CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 4 enrolled
Drug / intervention
Platelet rich fibrin matrixbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00956020
NCT00956020Phase 2Completed
CompareCT.gov

Evaluation of the Mechanism of Action of Platelet Rich Fibrin Matrix (PRFM) in Producing Skin Volume Augmentation

The New York Eye & Ear Infirmary·interventional·Posted Aug 11, 2009·Updated Dec 16, 2015

In Brief

A Phase 2 clinical trial evaluating Platelet rich fibrin matrix for Aging. Completed, enrolled 4 participants across 1 site.

Detailed Summary

Autologous platelet rich fibrin matrix will release growth factors which could increase the production of dermal proteins or affect the vascularity and status of neighboring tissues. This study is designed to evaluate the histologic and biochemical effect of injection of platelet rich fibrin matrix into the skin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAging
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 11, 2009
Enrollment StartOct 1, 2009
Primary CompletionFeb 1, 2011
Study CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.9 years ago

Interventions

Platelet rich fibrin matrixbiological

Single treatment with platelet rich fibrin matrix